The new approach, published in a Frontiers in Science lead article , could enable hospital pharmacists to rapidly create inexpensive, bespoke medicine cartridges—akin to tailoring espresso capsules to taste—for rare disease patients at their bedside.
Join the article authors Prof Raymond Schiffelers, Prof Sabine Fuchs, and Dr Alexandre Ceccaldi, plus Olivia Lewis and Alexandra Heumber Perry for an in-depth discussion on how NANOSPRESSO could boost access to personalized nucleic acid nanomedicines, even in low-resource settings.
This free webinar takes place on 9 July 2025, 16:00-17:30 CEST.
NANOSPRESSO: toward personalized locally produced nucleic acid nanomedicines | 9 July 2025 | Register
This event will explore:
why rare diseases demand a new model: the case for decentralizing personalized treatment production
overcoming pharmaceutical and regulatory barriers for nucleic acid therapeutics
RNA and LNP-based therapeutics: from pandemic response to personalized rare disease care
NANOSPRESSO: a scalable platform for bedside manufacturing of nucleic acid nanomedicines
ensuring quality, affordability, and equity in local production: practical, regulatory, and ethical considerations.
The authors and other experts will discuss how NANOSPRESSO could open up treatments for underfunded and underserved rare conditions worldwide—which affect 36 million patients in the EU alone.
Frontiers Forum Deep Dive sessions bring researchers, policy experts, and innovators together from around the world, to discuss a specific area of transformational science published in Frontiers' flagship, multidisciplinary journal, Frontiers in Science, and explore next steps for the field.